Weight loss is often presented as a serious problem in the media and social networks, but what therapeutic approaches are truly relevant for people who are obese?
All currently available scientific and clinical evidence emphasizes that for obesity treatment to be effective, it must be multidisciplinary and take into account the context and environment specific to each individual. In terms of medications, the first generation drug, orlistat, has long been prescribed to obese patients (BMI > 30 kg/m²). This molecule works by blocking the action of an enzyme that allows fat to be metabolized. However, although a reduction in the risk of diabetes has been observed, its effectiveness remains very limited.
In recent years, further therapeutic advances have materialized through the development of a new class of drugs, typically containing either liraglutide or semaglutide. These two GLP-1 analogue molecules increase the feeling of fullness and therefore allow people to better control their food intake.
Did you say appetite suppressant?
GLP-1 analogues are often referred to as “appetite suppressants” in the media. A term that some doctors consider inappropriate. In fact, these medications regulate appetite and increase feelings of fullness. The result: the desire to eat is no longer a central and constant problem, and patients regain control of their appetite without the feeling of hunger disappearing.
One thing is for sure: if these drugs can lead to significant weight loss, no one “miracle molecule” will be able to end obesity on its own. Let us remember that obesity is a global public health problem that requires continuing to offer comprehensive, interdisciplinary care tailored to each individual’s specific concerns.
Related Posts
Dengue: how New Caledonia got rid of it… without killing mosquitoes
These sleep disturbances increase the risk of cognitive decline and dementia.
